A presentation of

The Association of the Pharmaceutical Industry in Norway

(LMI)

LMI’s tasks/obkectives

LMI should be the obvious association (choice) both for the multinational companies and the smaller Norwegian entrepreneurs operating in the pharmaceutical / life science area

The associations objective is to protect the member companies’ interests related to

LMI in brief

52 members per December 1st 2012 More than 80 % of the total pharmaceutical sales Member companies employ about 4 000 people Cooperation and dialogue partner for the

authorities Liaison between industry and authorities

Drug sales in Norway 2012

18.6 billion (PRP) An increase of 0.3 in the PRP 12 billion (AIP) Growth of 1.4 percent in the DDD 9.1 billion in reimbursement 71 percent of expenditures financed by the public 25 percent VAT on all medicines Low rates Drug consumption is below average in the Nordic

countries

Organisation of the LMI Group

LMIs management is funded by the members through a service charge

Shareholders, board and management 14 committees, where employees of member

firms contribute Felleskatalogen AS and Farmastat AS are

independent subsidiaries The industry has 12 employees, Felleskatalogen

has 5 and Farmastat has 6 employees

Vision and goal

Vision

Medical advances for better health

Objectives / goals

Greater visibility and a good and trusting relationship with the outside world

Ensure that the Norwegian patients get quick access to medical innovations

Increase research, production and business development at pharmaceutical area in Norway

Ensuring a good framework for the industry

Our business areas

Visibility / communicationsPolicy work / conditionsOrganizationMember Services

Wealth creation and visibility (1)

LMI would like to take a new and clear role as a political influence, and contribute to a stronger visibility of the pharmaceutical industry's contribution to society.

LMI will be a future-oriented trade organization that promotes business and health policy views on behalf of the member-companies. In addition to protect industry interests, LMI will maintain a strong focus on the patient and the patients' rights.

Wealth creation and visibility (2)

There is a need for increased activity and efforts related to the promotion of research and industrial development in the pharmaceutical area in Norway, and a greater extent assure needs of small, established Norwegian companies.

LMI will maintain a membership service of high quality.

Working methods

Visibility Professional expertise and credibility Dialogue and cooperation rather than conflict Participation in broader health policy arenas Networking Dialogue with alliance partners

Transparency and tidiness

Clear and binding framework for cooperation through agreements (RHF DNLF, NFF, NSF, FFO)

Updated internal and self-imposed rules (Rules for drug information)

Industry internal awareness in relation to ethical issues

The principle is that all interactions should be open, verifiable, and withstand a critical light

What expertise do LMI have?

Research and development - clinical trials Approval of drugs / regulatory affairs Price, reimbursement and revenue Health Economics – Statistics Drug Policy / Health Policy Rules and regulations for marketing Industry Information Information - Press & Media Public Affairs Member Services and courses

Working methods